BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Commercial

Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

Related news

MISTMilestone Pharmaceuticals Inc.2026-04-10 12:00 EST

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

SENSSenseonics2026-04-24 11:00 EST

Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Stock data

Close
1.06 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States